ArticleSmall (Weinheim an der Bergstrasse, Germany)2011
Vaults engineered for hydrophobic drug delivery.
Article in Small (Weinheim an der Bergstrasse, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Addressing Critical Issues Related to Storage and Stability of the Vault Nanoparticle Expressed and Purified fromInternational journal of molecular sciences · 2023Article
- Tailored Functionalized Protein Nanocarriers for Cancer Therapy: Recent Developments and Prospects.Pharmaceutics · 2023Review
- Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Review
- Bioengineered recombinant vault nanoparticles coupled with NY-ESO-1 glioma-associated antigens induce maturation of native dendritic cells.Journal of neuro-oncology · 2020Article
- Latest Advances in the Development of Eukaryotic Vaults as Targeted Drug Delivery Systems.Pharmaceutics · 2019Review
- Protein-based nanoparticles in cancer vaccine development.Nanomedicine : nanotechnology, biology, and medicine · 2019Review
- Solution Structures of Engineered Vault Particles.Structure (London, England : 1993) · 2018Article
- Modulation of the Vault Protein-Protein Interaction for Tuning of Molecular Release.Scientific reports · 2017Article
- Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.Nanoscale · 2017Review
- Article
- Decrease in pH destabilizes individual vault nanocages by weakening the inter-protein lateral interaction.Scientific reports · 2016Article
- Dual pH- and Temperature-Responsive Protein Nanoparticles.European polymer journal · 2015Article
- Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery.ACS nano · 2014Article
- Genetically engineered nanocarriers for drug delivery.International journal of nanomedicine · 2014Review
- Structure and flexibility of nanoscale protein cages designed by symmetric self-assembly.Journal of the American Chemical Society · 2013Article
- Smart vaults: thermally-responsive protein nanocapsules.ACS nano · 2013Article
- Vault nanoparticles engineered with the protein transduction domain, TAT48, enhances cellular uptake.Integrative biology : quantitative biosciences from nano to macro · 2013Article
- In silico resurrection of the major vault protein suggests it is ancestral in modern eukaryotes.Genome biology and evolution · 2013Article
- Targeted vault nanoparticles engineered with an endosomolytic peptide deliver biomolecules to the cytoplasm.ACS nano · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The vault nanoparticle is one of the largest known ribonucleoprotein complexes in the sub-100 nm range. Highly conserved and almost ubiquitously expressed in eukaryotes, vaults form a large nanocapsule with a barrel-shaped morphology surrounding a large hollow interior. These properties make vaults an ideal candidate for development into a drug delivery vehicle. In this study, the first example of using vaults towards this goal is reported. Recombinant vaults are engineered to encapsulate the highly insoluble and toxic hydrophobic compound all-trans retinoic acid (ATRA) using a vault-binding lipoprotein complex that forms a lipid bilayer nanodisk. These recombinant vaults offer protection to the encapsulated ATRA from external elements. Furthermore, a cryo-electron tomography (cryo-ET) reconstruction shows the vault-binding lipoprotein complex sequestered within the vault lumen. Finally, these ATRA-loaded vaults show enhanced cytotoxicity against the hepatocellular carcinoma cell line HepG2. The ability to package therapeutic compounds into the vault is an important achievement toward their development into a viable and versatile platform for drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.